You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF

    SBC: SAVARA INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Persistent respiratory methicillin resistant Staphylococcus aureus MRSA infections have become increasingly common in cystic fibrosis CF patients with a prevalence of almost in CF patients in the US This is concerning as MRSA positivity is associated with a faster decline of lung function and a years shorter median life expectancy compared to CF p ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Plasmodium Falciparum Whole Sporozoite Malaria Vaccine

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION provided by applicant The ideal tool for eliminating Plasmodium falciparum Pf the causative agent of of all malaria deaths would be a highly effective vaccine that prevents blood stage infection and thereby prevents the disease and transmission The only immunogens demonstrated in humans to be able to induce andgt protective efficacy that is sustained months are ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Plasmodium Falciparum Whole Sporozoite Malaria Vaccine

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION provided by applicant The ideal tool for eliminating Plasmodium falciparum Pf the causative agent of of all malaria deaths would be a highly effective vaccine that prevents blood stage infection and thereby prevents the disease and transmission The only immunogens demonstrated able to induce andgt sustained months protective efficacy in humans are Pf sporozoit ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Biomarker Quantitation by NP-MS Tissue Imaging.

    SBC: IONWERKS INC            Topic: NIDA

    DESCRIPTION provided by applicant MALDI tissue imaging when enabled by Nanoparticulate NP Matrix implantation is maturing into a useful preclinical tool for biomarker and drug discovery in our laboratory and at NIDA IRP Quantitatively reproducible images from serial coronal sections suggest that relative quantitation is now possible in rodent models of disease and injury Nanoparticulate ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Optimization of a DNA Subunit Regimen for an HIV Vaccine

    SBC: PROFECTUS BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Our primary approach to develop an effective prophylactic vaccine against HIV utilizes a novel immunogen called the Full Length Single Chain FLSC that consists of gp derived from HIV BaL genetically linked via a amino acid linker to the D D domains of human CD Rhesus macaques were inoculated with rhFLSC a surrogate version of FLSC that contains CD derived from rhe ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. An Intuitive Prosthetic System for Upper Extremity Amputees

    SBC: INFINITE BIOMEDICAL TECHNOLOGIES, LLC            Topic: NINDS

    DESCRIPTION (provided by applicant): There are well over 100,000 people living with upper limb loss in the United States today and 1 in 12 new amputations are of the upper limb. The loss of an upper limb is devastating to a person's quality of life, theirwork productivity and it bring about many psychosocial challenges. While there have been exciting technological advances which promise the a ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. An Intuitive Prosthetic System for Upper Extremity Amputees

    SBC: INFINITE BIOMEDICAL TECHNOLOGIES, LLC            Topic: 102

    DESCRIPTION provided by applicant There are well over people living with upper limb loss in the United States today and in new amputations are of the upper limb The loss of an upper limb is devastating to a personandapos s quality of life their work productivity and it bring about many psychosocial challenges While there have been exciting technological advances which promise th ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  8. A New Tool Kit for Whole-Genome Mapping and Complementation in Drosophila

    SBC: GENETIVISION CORPORATION            Topic: NIGMS

    DESCRIPTION (provided by applicant): The ultimate goal of this proposal is to generate, maintain, and distribute a new collection of duplication stocks that covers nearly the entire euchromatic autosomal portion of the Drosophila melanogaster genome. Sincethis collection will represent a powerful new set of tools that will benefit virtually all Drosophila geneticists, t is likely that there will b ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Enabling use of blood spot cards for accurate high throughput Fragile X screening

    SBC: ASURAGEN, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): The long term goal of this project is to develop accurate, rapid, high throughput and cost-effective screening for fragile X syndrome (FXS) and related disorders. FXS is the most common known genetic cause of autism andinherited intellectual disability, and affects roughly 1 in 4,000 males and 1 in 6,000 females. The incidence of fragile X carriers is as high a ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Low-Dose MRI-Compatible Molecular Breast Imaging Device

    SBC: WEINBERG MEDICAL PHYSICS, INC.            Topic: 102

    DESCRIPTION provided by applicant Contrast enhanced MRI has been proven to be a very sensitive modality for the early diagnosis of breast cancer in young women and or in women with radiographically dense breasts The American Cancer Society recommends that high risk women with lifetime risk greater than should receive annual breast MRI screening Depending on the practitioner and study char ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government